Drugs / rVSV∆G-SEBOV-GP Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05724472 | Jun 2023 → Jan 2024 | Ebola hemorrhagic fever | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rVSV∆G-SEBOV-GP Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05724472 ↗ |
| Modality | Vaccine | “study vaccine named rVSVΔG-SEBOV-GP Vaccine” NCT05724472 ↗ |
| Route | Intramuscular | “rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10\^6 pfu intramuscularly Day 1” NCT05724472 ↗ |